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Abstract
Background: Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be
a variant of multiple myeloma. It is an aggressive disease with a poor clinical response to standard
chemotherapeutic agents.
Case presentation: A novel regimen consisting of bortezomib, doxorubicin, and dexamethasone
is currently under active evaluation for the treatment of multiple myeloma. We employed this
combination as front-line chemoinduction therapy for a case of primary PCL.
Conclusion:  Complete remission was achieved with rapid normalization of hematologic
parameters. The combination of bortezomib, doxorubicin and dexamethasone demonstrates
promise in the treatment of PCL.
Background
Plasma cell leukemia (PCL) is a rare but aggressive form
of lymphoproliferative disorder characterized by malig-
nant plasma cells in the bone marrow and peripheral
blood. This entity is considered to be a variant of multiple
myeloma (MM) that can present de novo in patients with
no preceding MM or in patients with established MM after
leukemic transformation [1]. Although PCL and MM are
closely related disease entities, the prognosis of PCL
patients treated with standard chemotherapy has consist-
ently been shown to be inferior to that of MM patients
[1,2]. Due to the rarity of PCL, there has been a paucity of
studies evaluating optimal treatment strategies.
Bortezomib was approved for the treatment of MM in
patients who have received and failed to respond to at
least one prior therapy [3]. Bortezomib represents a new
class of anti-neoplastic medications that selectively inhib-
its the activity of the 26S proteasome complex of the cell
[3]. The mechanisms underlying the anti-neoplastic
effects of bortezomib include NF-κB inhibition, upregula-
tion of apoptotic pathways, and effects on the tumor
microenvironment [3]. While the therapeutic efficacy of
bortezomib is well established for MM, only several case
reports have been published reporting efficacy of it in the
treatment of PCL either as monotherapy or in combina-
tion with other agents [4-7]. A recent retrospective survey
of twelve cases of PCL treated with bortezomib showed an
initial response rate of 92% [8].
Here, we detail our experience in the management of a
case of primary PCL. This case is interesting in several
ways. From the diagnostic and prognostic perspectives,
the malignant plasma cells showed an unusual "hairy-
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cell" morphology, harbored a t(11;14), and strongly
expressed cyclin D1. From the treatment perspective, com-
plete remission was achieved with a novel combination
regimen of bortezomib, doxorubicin, and dexamethasone
as first-line induction chemotherapy. This combination is
currently under active evaluation for the treatment of MM
[9] but has not been extensively studied for the treatment
of PCL. Furthermore, this case highlights two important
toxicities related to the use of high-dose bortezomib and
their impact on management.
Case presentation
A 54 year-old African-American man with no significant
past medical history was transferred to our institution
with right sided abdominal discomfort for 1 week. On
admission, he noted recent onset of polyuria, anorexia,
fatigue and dyspnea. Physical examination was notable
for right upper quadrant abdominal tenderness and
absence of lymphadenopathy or splenomegaly. An elec-
trolyte panel revealed hypercalcemia (14 mg/dL) in the
setting of an elevated creatinine level (3.2 mg/dL). He had
a white blood cell count of 135,000/μL, hemoglobin con-
centration of 8.4 g/dL, and platelet count of 76,000/μL.
Peripheral blood smear revealed an increased number of
leukocytes that consisted of a population of atypical-
appearing lymphoid cells of variable size and appearance
with numerous cytoplasmic hairy projections and deeply
basophilic cytoplasm (Figure 1). The cells did not show
microscopic features characteristic of mature plasma cells.
A core biopsy revealed a hypercellular bone marrow
(90%) that was replaced by a population of atypical cells
similar to the ones seen in peripheral blood. Flow cytom-
etry and immunohistochemistry (IHC) studies of the cells
revealed a population that was deficient in B and T cell
specific markers but strongly expressed CD38, CD138 and
cytoplasmic lambda light chain. Serum protein electro-
phoresis revealed an M-spike that was identified as free
lambda chain on immunofixation. Serum lambda free
light chain level was correspondingly elevated. The com-
bined clinical and laboratory findings supported the diag-
nosis of plasma cell leukemia.
Additional prognostic studies included the following:
beta-2 microglobulin, 6893 ng/mL (normal range: 609–
2366); serum albumin, 3.8 g/dL (3.5–5.0); and lactate
dehydrogenase, 191 U/L (<240). Serum immunoglobulin
levels of all isotypes were low. A skeletal survey was nega-
tive. Conventional cytogenetic and interphase FISH anal-
ysis revealed a CCND1/IGH gene fusion rearrangement
mediated by an unbalanced t(11;14)(q13;q32). This
translocation brings the cyclin D1 oncogene in close prox-
imity to the powerful Eμ enhancer of the IgH locus [10].
Cyclin D1 expression was correspondingly strong on IHC
staining.
After normalization of his calcium and creatinine levels
with aggressive fluid resuscitation, induction chemother-
apy with bortezomib, doxorubicin, and dexamethasone
was initiated. Chemotherapy was administered over the
course of 5 cycles (Table 1) which resulted in a rapid sup-
pression of the white blood cell count in association with
a more gradual recovery of hemoglobin concentration
and platelet count to near-normal and normal levels,
respectively (Figure 2). The serum free kappa to lambda
light chain ratio normalized after one cycle of chemother-
apy and remained normal for the remaining cycles (Figure
2). A restaging skeletal survey revealed no interval devel-
opment of bony lesions. A repeat bone marrow aspirate
and biopsy showed hypocellularity (<5%) with no mor-
phologic, cytogenetic, or immunophenotypic evidence of
disease. The patient was in stringent complete remission
based on the International Myeloma Working Group
(IMWG) criteria [11]. At the time of publication, the
patient is undergoing evaluation for either an autologous
or allogeneic bone marrow transplant to consolidate treat-
ment.
Chemoinduction was complicated by significant treat-
ment related toxicities to the lung and peripheral nerves.
After the first dose, the patient developed a non-produc-
tive cough without dyspnea, hypoxia or respiratory com-
promise. Computed tomography imaging of the chest
demonstrated bilateral pleural effusions with extensive
upper-lobe ground-glass opacities. Transbronchial biopsy
and bronchoalveolar lavage failed to show any infectious
organisms or malignancy. The pulmonary finding was
Peripheral blood smear showing the morphology of patient's  leukemic cells Figure 1
Peripheral blood smear showing the morphology of 
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therefore felt to be secondary to bortezomib which has
been reported in the past [12]. The patient received a high-
dose dexamethasone taper over a 4-week period which
resulted in significant resolution of his cough and imag-
ing abnormalities with no subsequent recurrence.
The patient also experienced grade 2 to 3 peripheral neu-
ropathy which is a well documented side effect of borte-
zomib therapy [13]. Bilateral numbness, tingling, burning
pain, and sensory loss in his toes and feet occurred soon
after the first cycle. His symptoms worsened to involve
motor weakness and progressed proximally to involve his
lower extremities to the level of the knee after the second
cycle necessitating dose reduction or deletion of borte-
zomib on cycles 3, 4, and 5. Trials of gabapentin, pregab-
alin, mexiletine, duloxetine, topiramate, amitriptyline,
and methadone were attempted but all with either signif-
icant side effects or lack of symptomatic control.
Discussion
Although PCL is a rare entity representing only 0.3% of
acute leukemia cases, it is an aggressive disease with a
median overall survival of less than one year with conven-
tional chemotherapy alone [1]. Several genomic aberra-
tions and immunohistochemical markers have been
identified as prognostic indicators for MM including two
markers found in our case: t(11;14) and cyclin D1 [10].
The t(11;14) which frequently results in upregulation of
Table 1: Bortezomib, doxorubicin, dexamethasone chemotherapy regimen
Drug Cyclea
#1 #2 #3b #4 #5c
Bortezomib 1.3 mg/m2 1.3 mg/m2 1.0 mg/m2 Not given 0.7 mg/m2
Doxorubicin 5 mg/m2 5 mg/m2 5 mg/m2 4 mg/m2 10 mg/m2
Dexamethasone (IV) 40 mg 40 mg 40 mg 40 mg 40 mg (PO)
a Each cycle with the exception of cycle #5 consisted of four scheduled doses on days 1, 4, 8, and 11. All three drugs were administered on each day 
unless otherwise stated. A cycle was started every 28 days.
b Bortezomib and doxorubicin were held on cycle 3, day 11 due to progressive peripheral neuropathy.
c Cycle #5 consisted of one dose of bortezomib on day 1, two doses of doxorubicin on days 1, and 8 and four doses of oral dexamethasone on days 
1, 2, 8, and 9.
Hematologic parameters and free kappa/lambda light chain ratio over the course of chemoinduction Figure 2
Hematologic parameters and free kappa/lambda light chain ratio over the course of chemoinduction. The num-
bers above the vertical columns represent cycles. Horizontal lines represent the lower and uppers limits of normal. In the 
hemoglobin graph, only the lower limit line is shown. Day "0" refers to the day of admission.Cases Journal 2009, 2:121 http://www.casesjournal.com/content/2/1/121
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the oncogene cyclin D1, is correlated with a neutral or
favorable prognosis in MM [10,14]. Correspondingly, cyc-
lin D1 expression has also been associated with prolonged
overall survival [10,15]. Cytogenetic abnormalities are
also commonly observed in primary PCL with up to 70%
of cases harboring the t(11;14)(q13;q32) [16]. A recent
study by Tiedemann et al. reported no significant differ-
ence in overall survival between t(11;14)(q13;q32)-posi-
tive and negative PCL patients [16]. Further studies are
warranted to confirm this finding and identify additional
prognostic markers in PCL.
Bortezomib is effective as a single agent in the treatment
of MM. Esparis-Ogando et al. also described the successful
treatment of a patient with secondary PCL with borte-
zomib alone [6]. However, a highly synergistic in vitro
anti-tumor effect between bortezomib and genotoxic
chemotherapeutic agents including doxorubicin and mel-
phalan has been shown in MM cell lines and primary MM
cells [17]. This finding forms a rational basis for combina-
tion therapy in MM. Indeed, a recent phase III trial com-
paring bortezomib alone or in combination with
pegylated liposomal doxorubicin in patients with
relapsed or refractory myeloma reported an increase in
median time to progression, median duration of response
and 15-month survival rate [18]. Based on the above find-
ings, we elected to use a bortezomib-based combination
regimen for our patient. The combination of bortezomib,
doxorubicin and dexamethasone (PAD) has previously
been shown to be highly active in MM [9] but has not
been extensively studied in PCL. In this report, we show
that this regimen has clinical activity against t(11;14)+/
cyclin D1+ PCL.
Peripheral neuropathy is a common toxicity associated
with bortezomib. In a study of 256 MM patients treated
with bortezomib, grade 1–2 peripheral neuropathy
occurred in 22% of patients [13]. Our patient developed
symptoms of neuropathy shortly after the first cycle of
bortezomib. Symptoms remained even after dose reduc-
tion and discontinuation in subsequent cycles. Persistence
of symptoms has been shown to occur in about 30% of
patients with severe neuropathy [13]. As illustrated in this
case, achieving symptomatic relief can be a challenging
process requiring empiric trials of many classes of medica-
tions.
Unlike peripheral neuropathy, severe pulmonary compli-
cations occur rarely with bortezomib and have only been
reported in several case reports [12,19,20]. It is of interest
that many of the reported cases have occurred in patients
of Japanese origin suggesting a genetic predisposition to
this complication [12,19]. Our patient who is African-
American developed a non-productive cough, pleural
effusion and ground-glass opacities on CT imaging shortly
after his first dose of bortezomib. His symptoms and
imaging abnormalities responded favorably and quickly
to a high-dose dexamethasone taper. The clinical course
of our patient was remarkably similar to that of prior
reported cases [12,19,20]. Our experience further sup-
ports the use of high-dose steroids early in the manage-
ment of pulmonary complications caused by bortezomib.
This case demonstrates that the combination of borte-
zomib, doxorubicin, and dexamethasone is relatively
well-tolerated and has clinical utility in the treatment of
t(11;14)-positive plasma cell leukemias. Further evalua-
tion of the combination in this setting is warranted.
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